Search results for

The 20 years since Managing IP was launched have seen great shifts in the global economy, the profile of IP assets and the daily work of IP practitioners. James Nurton introduces a look back – and forward

As Latin America becomes an increasingly important market, rights owners must be aware of the evolving laws around issues such as digital rights and non-traditional trade marks in the region. Managing IP discussed the key challenges with several prominent members of the Latin American IP community

Key events year by year 1990 October: Biggest patent damages award

In another blow to multinational pharmaceutical companies in India, the Chennai Patent Office has invalidated a key patent owned by Swiss drug maker F Hoffmann La Roche, allowing generic competitors to enter the market

On April 30 2010, the Office of the United States Trade Representative (USTR) published its 2010 Special 301 Report examining the application and effectiveness of intellectual property rights enforcement (IPR) by countries around the world. The USTR bases its opinion on submissions received from different groups, including lobbies such as the Pharmaceutical Researchers and Manufacturers of America and the International Intellectual Property Alliance, as well as non-governmental organisations (NGOs) like Doctors without Borders.

On World IP Day, April 26 2010, key stakeholders of the Indonesian IP community announced the formation of an Indonesian arbitration centre specifically designed to handle intellectual property disputes. The arbitration centre will provide arbitration and mediation services for those with civil intellectual property disputes, which are now handled exclusively by the Commercial Court.

The April 2010 edition of the Guidelines for Examination in the European Patent Office has been released and applies from April 1 2010. The Guidelines constitute the EPO counterpart to the Manual of Patent Examining Procedure (MPEP) of the United States Patent and Trademark Office (USPTO).

In a recent decision (G2/08) published on February 19 2010 the Enlarged Board of Appeal (EBA) of the European Patent Office (EPO) ruled, inter alia, on the patentability of claims relating to the use of a known active ingredient in the preparation of a medicament for the treatment of a known medical indication where the treatment differs merely with respect to the administration regimen (generally referred to as dosage regimen).

Fabrice Mattei and Prasit Siricheepchaiyan of Rouse review trends in drafting, filing and prosecuting patents in Thailand

Marybeth Peters Copyright law's twin challenges